TRIM21: A cytosolic Fc receptor with broad antibody isotype specificity

Immunological Reviews

Volumn 268, Issue 1, 2015, Pages 328-339

  Foss, Stian ^a,b   Watkinson, Ruth ^c   Sandlie, Inger ^a,b   James, Leo C ^c   Andersen, Jan Terje ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Antibodies; Fc receptor; Intracellular immunity; Isotype; TRIM21; Virus

Indexed keywords

ANTIBODY; AUTOANTIGEN; FC RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; NEUTRALIZING ANTIBODY; PROTEIN KINASE SYK; TRANSCRIPTION FACTOR; TRIPARTITE MOTIF CONTAINING PROTEIN 21; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN FC FRAGMENT; PROTEIN BINDING; RIBONUCLEOPROTEIN; SS-A ANTIGEN;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN PRESENTATION; CARBOXY TERMINAL SEQUENCE; CELL MEDIATED CYTOTOXICITY; CRYSTAL STRUCTURE; CYTOKINE RELEASE; CYTOSOL; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; INFLUENZA; NONHUMAN; NUCLEAR PORE COMPLEX; PERSISTENT VIRUS INFECTION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTECTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RHINOVIRUS; RING FINGER MOTIF; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS NEUTRALIZATION; VIRUS PARTICLE; ANIMAL; CHEMISTRY; ENZYME ACTIVATION; HOST PATHOGEN INTERACTION; IMMUNITY; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; PROTEIN DOMAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CYTOSOL; ENZYME ACTIVATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN M; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; RIBONUCLEOPROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84945265000     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12363     Document Type: Review

References (128)

1. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002;2:706-713.
2. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337:183-186.
3. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013;31:705-742.
4. Dimmock NJ. Neutralization of animal viruses. Curr Top Microbiol Immunol 1993;183:1-149.
5. Parren PW, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001;77:195-262.
6. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 2014;20:143-151.
7. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014;158:1243-1253.
8. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
9. Brandtzaeg P. Secretory IgA: designed for anti-microbial defense. Front Immunol 2013;4:222.
10. Rojas R, Apodaca G. Immunoglobulin transport across polarized epithelial cells. Nat Rev Mol Cell Biol 2002;3:944-955.
11. Dickinson BL, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 1999;104:903-911.
12. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res 2002;25:97-113.
13. Spiekermann GM, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 2002;196:303-310.
14. He W, Ladinsky MS, Huey-Tubman KE, Jensen GJ, McIntosh JR, Bjorkman PJ. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature 2008;455:542-546.
15. Tzaban S, et al. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol 2009;185:673-684.
16. Ko SY, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014;514:642-645.
17. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci USA 2011;108:4388-4393.
18. Sholukh AM, et al. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 2015;33:2086-2095.
19. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 2006;168:1210-1226.
20. Bai Y, et al. Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci USA 2011;108:18406-18411.
21. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996;272:104-107.
22. Roost HP, et al. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc Natl Acad Sci USA 1995;92:1257-1261.
23. Bachmann MF, et al. The role of antibody concentration and avidity in antiviral protection. Science 1997;276:2024-2027.
24. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006;6:231-243.
25. Leung DT, et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis 2004;190:379-386.
26. Sumida SM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005;174:7179-7185.
27. Schrader JW, McLean GR. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies. Immunol Lett 2007;112:58-60.
28. Kwong PD, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420:678-682.
29. McEwan WA, James LC. TRIM21-dependent intracellular antibody neutralization of virus infection. Prog Mol Biol Transl Sci 2015;129:167-187.
30. Watkinson RE, McEwan WA, James LC. Intracellular antibody immunity. J Clin Immunol 2014;34(Suppl):S30-S34.
31. Randow F, MacMicking JD, James LC. Cellular self-defense: how cell-autonomous immunity protects against pathogens. Science 2013;340:701-706.
32. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA 2010;107:19985-19990.
33. Hauler F, Mallery DL, McEwan WA, Bidgood SR, James LC. AAA ATPase p97/VCP is essential for TRIM21-mediated virus neutralization. Proc Natl Acad Sci USA 2012;109:19733-19738.
34. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 2013;14:327-336.
35. Bidgood SR, Tam JC, McEwan WA, Mallery DL, James LC. Translocalized IgA mediates neutralization and stimulates innate immunity inside infected cells. Proc Natl Acad Sci USA 2014;111:13463-13468.
36. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012;11:311-331.
37. Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004;4:89-99.
38. Bruhns P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009;113:3716-3725.
39. Reymond A, et al. The tripartite motif family identifies cell compartments. EMBO J 2001;20:2140-2151.
40. Yang Y, Eversole T, Lee DJ, Sontheimer RD, Capra JD. Protein-protein interactions between native Ro52 and immunoglobulin G heavy chain. Scand J Immunol 1999;49:620-628.
41. Rhodes DA, et al. The 52 000 MW Ro/SS-A autoantigen in Sjogren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology 2002;106:246-256.
42. Rhodes DA, Trowsdale J. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Mol Immunol 2007;44:2406-2414.
43. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci USA 2007;104:6200-6205.
44. Keeble AH, Khan Z, Forster A, James LC. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci USA 2008;105:6045-6050.
45. Ikeda K, Inoue S. TRIM proteins as RING finger E3 ubiquitin ligases. Adv Exp Med Biol 2012;770:27-37.
46. Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 2005;3:799-808.
47. Rajsbaum R, Garcia-Sastre A, Versteeg GA. TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol 2014;426:1265-1284.
48. Nakayama EE, Shioda T. Anti-retroviral activity of TRIM5 alpha. Rev Med Virol 2010;20:77-92.
49. Rhodes DA, de Bono B, Trowsdale J. Relationship between SPRY and B30.2 protein domains. Evolution of a component of immune defence? Immunology 2005;116:411-417.
50. Napolitano LM, Meroni G. TRIM family: pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life 2012;64:64-71.
51. Sanchez JG, Okreglicka K, Chandrasekaran V, Welker JM, Sundquist WI, Pornillos O. The tripartite motif coiled-coil is an elongated antiparallel hairpin dimer. Proc Natl Acad Sci USA 2014;111:2494-2499.
52. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001;276:16469-16477.
53. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000;406:267-273.
54. Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci USA 2015;112:833-838.
55. Idusogie EE, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000;164:4178-4184.
56. Vaughn DE, Bjorkman PJ. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure 1998;6:63-73.
57. Oganesyan V, et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem 2014;289:7812-7824.
58. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 1981;20:2361-2370.
59. Kato K, et al. Model for the complex between protein G and an antibody Fc fragment in solution. Structure 1995;3:79-85.
60. Sprague ER, Wang C, Baker D, Bjorkman PJ. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol 2006;4:e148.
61. Lewis MJ, Pleass RJ, Batten MR, Atkin JD, Woof JM. Structural requirements for the interaction of human IgA with the human polymeric Ig receptor. J Immunol 2005;175:6694-6701.
62. Bonner A, Almogren A, Furtado PB, Kerr MA, Perkins SJ. The nonplanar secretory IgA2 and near planar secretory IgA1 solution structures rationalize their different mucosal immune responses. J Biol Chem 2009;284:5077-5087.
63. Pleass RJ, Dunlop JI, Anderson CM, Woof JM. Identification of residues in the CH2/CH3 domain interface of IgA essential for interaction with the human fcalpha receptor (FcalphaR) CD89. J Biol Chem 1999;274:23508-23514.
64. Carayannopoulos L, Hexham JM, Capra JD. Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1. J Exp Med 1996;183:1579-1586.
65. Woof JM. The human IgA-Fc alpha receptor interaction and its blockade by streptococcal IgA-binding proteins. Biochem Soc Trans 2002;30:491-494.
66. Pleass RJ, Areschoug T, Lindahl G, Woof JM. Streptococcal IgA-binding proteins bind in the Calpha 2-Calpha 3 interdomain region and inhibit binding of IgA to human CD89. J Biol Chem 2001;276:8197-8204.
67. Ghumra A, et al. Structural requirements for the interaction of human IgM and IgA with the human Fcalpha/mu receptor. Eur J Immunol 2009;39:1147-1156.
68. Senior BW, Woof JM. Sites in the CH3 domain of human IgA1 that influence sensitivity to bacterial IgA1 proteases. J Immunol 2006;177:3913-3919.
69. McEwan WA, et al. Regulation of virus neutralization and the persistent fraction by TRIM21. J Virol 2012;86:8482-8491.
70. Biedermannova L, Riley K, Berka K, Hobza P, Vondrasek J. Another role of proline: stabilization interactions in proteins and protein complexes concerning proline and tryptophane. Phys Chem Chem Phys 2008;10:6350-6359.
71. Cao K, Nakajima R, Meyer HH, Zheng Y. The AAA-ATPase Cdc48/p97 regulates spindle disassembly at the end of mitosis. Cell 2003;115:355-367.
72. Fu X, Ng C, Feng D, Liang C. Cdc48p is required for the cell cycle commitment point at Start via degradation of the G1-CDK inhibitor Far1p. J Cell Biol 2003;163:21-26.
73. Janiesch PC, et al. The ubiquitin-selective chaperone CDC-48/p97 links myosin assembly to human myopathy. Nat Cell Biol 2007;9:379-390.
74. Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol 2012;14:117-123.
75. Hetzer M, Meyer HH, Walther TC, Bilbao-Cortes D, Warren G, Mattaj IW. Distinct AAA-ATPase p97 complexes function in discrete steps of nuclear assembly. Nat Cell Biol 2001;3:1086-1091.
76. Ramadan K, et al. Cdc48/p97 promotes reformation of the nucleus by extracting the kinase Aurora B from chromatin. Nature 2007;450:1258-1262.
77. Zhang X, et al. Structure of the AAA ATPase p97. Mol Cell 2000;6:1473-1484.
78. Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 2001;3:740-744.
79. Beskow A, Grimberg KB, Bott LC, Salomons FA, Dantuma NP, Young P. A conserved unfoldase activity for the p97 AAA-ATPase in proteasomal degradation. J Mol Biol 2009;394:732-746.
80. Isakov E, Stanhill A. Stalled proteasomes are directly relieved by P97 recruitment. J Biol Chem 2011;286:30274-30283.
81. Reddy VS, Natchiar SK, Stewart PL, Nemerow GR. Crystal structure of human adenovirus at 3.5 A resolution. Science 2010;329:1071-1075.
82. Gallastegui N, Groll M. The 26S proteasome: assembly and function of a destructive machine. Trends Biochem Sci 2010;35:634-642.
83. Xie Y. Structure, assembly and homeostatic regulation of the 26S proteasome. J Mol Cell Biol 2010;2:308-317.
84. Fletcher AJ, Mallery DL, Watkinson RE, Dickson CF, James LC. Sequential ubiquitination and deubiquitination enzymes synchronize the dual sensor and effector functions of TRIM21. Proc Natl Acad Sci USA 2015;112:10014-10019.
85. David Y, Ziv T, Admon A, Navon A. The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines. J Biol Chem 2010;285:8595-8604.
86. Hofmann RM, Pickart CM. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 1999;96:645-653.
87. Wickliffe KE, Lorenz S, Wemmer DE, Kuriyan J, Rape M. The mechanism of linkage-specific ubiquitin chain elongation by a single-subunit E2. Cell 2011;144:769-781.
88. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol 2006;208:270-282.
89. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008;1:11-22.
90. Kerr MA. The structure and function of human IgA. Biochem J 1990;271:285-296.
91. Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003;21:177-204.
92. Suzuki T, et al. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proc Natl Acad Sci USA 2015;112:7809-7814.
93. Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002;83(Pt 9):2091-2108.
94. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
95. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 2008;8:911-922.
96. Schaefer L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J Biol Chem 2014;289:35237-35245.
97. Pertel T, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011;472:361-365.
98. Xia ZP, et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009;461:114-119.
99. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006;22:245-257.
100. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol 2006;8:398-406.
101. Lee MJ, Lee BH, Hanna J, King RW, Finley D. Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes. Mol Cell Proteomics 2011;10:R110 003871.
102. van der Merwe PA, Dushek O. Mechanisms for T cell receptor triggering. Nat Rev Immunol 2011;11:47-55.
103. McEwan WA, Mallery DL, Rhodes DA, Trowsdale J, James LC. Intracellular antibody-mediated immunity and the role of TRIM21. BioEssays 2011;33:803-809.
104. Fuchs R, Blaas D. Uncoating of human rhinoviruses. Rev Med Virol 2010;20:281-297.
105. Burckhardt CJ, Suomalainen M, Schoenenberger P, Boucke K, Hemmi S, Greber UF. Drifting motions of the adenovirus receptor CAR and immobile integrins initiate virus uncoating and membrane lytic protein exposure. Cell Host Microbe 2011;10:105-117.
106. Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J Virol 2005;79:1992-2000.
107. Leopold PL, et al. Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene Ther 2000;11:151-165.
108. Greber UF, Suomalainen M, Stidwill RP, Boucke K, Ebersold MW, Helenius A. The role of the nuclear pore complex in adenovirus DNA entry. EMBO J 1997;16:5998-6007.
109. Brabec-Zaruba M, Pfanzagl B, Blaas D, Fuchs R. Site of human rhinovirus RNA uncoating revealed by fluorescent in situ hybridization. J Virol 2009;83:3770-3777.
110. Brabec M, et al. Opening of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating monitored by single-organelle flow analysis. J Virol 2005;79:1008-1016.
111. Booy FP, Roden RB, Greenstone HL, Schiller JT, Trus BL. Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J Mol Biol 1998;281:95-106.
112. Emini EA, Kao SY, Lewis AJ, Crainic R, Wimmer E. Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies. J Virol 1983;46:466-474.
113. Emini EA, Ostapchuk P, Wimmer E. Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization. J Virol 1983;48:547-550.
114. Smith JG, Cassany A, Gerace L, Ralston R, Nemerow GR. Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport. J Virol 2008;82:6492-6500.
115. Mandel B. The interaction of neutralized poliovirus with HeLa cells. I. Adsorption. Virology 1967;31:238-247.
116. Toogood CI, Crompton J, Hay RT. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol 1992;73(Pt 6):1429-1435.
117. Varghese R, Mikyas Y, Stewart PL, Ralston R. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J Virol 2004;78:12320-12332.
118. Wetz K, Willingmann P, Zeichhardt H, Habermehl KO. Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion. Arch Virol 1986;91:207-220.
119. Wohlfart CE, Svensson UK, Everitt E. Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera. J Virol 1985;56:896-903.
120. Beuzon CR, Salcedo SP, Holden DW. Growth and killing of a Salmonella enterica serovar Typhimurium sifA mutant strain in the cytosol of different host cell lines. Microbiology 2002;148(Pt 9):2705-2715.
121. Birmingham CL, Brumell JH. Autophagy recognizes intracellular Salmonella enterica serovar Typhimurium in damaged vacuoles. Autophagy 2006;2:156-158.
122. Rakebrandt N, Lentes S, Neumann H, James LC, Neumann-Staubitz P. Antibody- and TRIM21-dependent intracellular restriction of Salmonella enterica. Pathog Dis 2014;72:131-137.
123. Watkinson RE, Tam JC, Vaysburd MJ, James LC. Simultaneous neutralization and innate immune detection of a replicating virus by TRIM21. J Virol 2013;87:7309-7313.
124. Vaysburd M, et al. Intracellular antibody receptor TRIM21 prevents fatal viral infection. Proc Natl Acad Sci USA 2013;110:12397-12401.
125. Moore ML, McKissic EL, Brown CC, Wilkinson JE, Spindler KR. Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase. J Virol 2004;78:5584-5590.
126. Welton AR, Gralinski LE, Spindler KR. Mouse adenovirus type 1 infection of natural killer cell-deficient mice. Virology 2008;373:163-170.
127. Charles PC, Guida JD, Brosnan CF, Horwitz MS. Mouse adenovirus type-1 replication is restricted to vascular endothelium in the CNS of susceptible strains of mice. Virology 1998;245:216-228.
128. Tam JC, Bidgood SR, McEwan WA, James LC. Intracellular sensing of complement C3 activates cell autonomous immunity. Science 2014;345:1256070.